Bright Minds Biosciences Inc. (DRUG) shareholders
Close on Nov 18, 2026Market cap $158.52MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ian McDonald | 1,396,665 | 13.70% | 13D (active) amendment | Nov 4, 2024 |
| Janus Henderson Group PLC | 1,284,324 | 13.10% | 13G (passive) amendment | Mar 31, 2026 |
| Cormorant Asset Management, LP Joint filing with Bihua Chen (10.88%) | 1,059,331 | 10.88% | 13G (passive) amendment | Jan 31, 2026 |
| Chen Bihua Joint filing with Cormorant Asset Management, LP (9.71%) | 950,000 | 9.71% | 13G (passive) amendment | Apr 28, 2026 |
| Bihua Chen Joint filing with Cormorant Asset Management, LP (9.17%) | 900,000 | 9.17% | 13G (passive) amendment | Jun 30, 2026 |
| Vivo Opportunity, LLC Joint filing with Vivo Opportunity Fund Holdings, L.P. (5.20%) | 504,645 | 5.20% | 13G (passive) amendment | Mar 31, 2026 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.00%) | 492,319 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (6.40%) | 454,184 | 6.40% | 13G (passive) | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (6.30%), Joseph Edelman (6.30%) | 444,649 | 6.30% | 13G (passive) amendment | Mar 31, 2025 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.58%), Phillip Gross (5.58%) | 395,743 | 5.58% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DRUG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,349,107 | 17.67% | $94.82M | New | 0.04% |
| Cormorant Asset Management, LP | 900,000 | 11.79% | $63.18M | −159,331 | 3.24% |
| BlackRock, Inc. | 686,184 | 8.99% | $48.17M | +64,251 | 0.00% |
| Vivo Capital, LLC | 557,172 | 7.30% | $39.11M | – | 3.57% |
| Vestal Point Capital, LP | 545,000 | 7.14% | $38.26M | +52,681 | 0.89% |
| Braidwell LP | 483,822 | 6.34% | $33.96M | −55,886 | 1.26% |
| Driehaus Capital Management LLC | 433,377 | 5.68% | $30.42M | +862 | 0.18% |
| Balyasny Asset Management L.P. | 345,053 | 4.52% | $24.22M | +47,895 | 0.03% |
| Adage Capital Partners Gp, L.L.C. | 335,000 | 4.39% | $23.52M | −160,743 | 0.03% |
| Point72 Asset Management, L.P. | 327,416 | 4.29% | $22.98M | New | 0.03% |
| Deerfield Management Company, L.P. (Series C) | 283,000 | 3.71% | $19.87M | – | 0.21% |
| Ra Capital Management, L.P. | 265,000 | 3.47% | $18.60M | – | 0.16% |
| Parkman Healthcare Partners LLC | 205,053 | 2.69% | $14.39M | +164,955 | 1.47% |
| Mpm Bioimpact LLC | 202,114 | 2.65% | $14.19M | −10,061 | 0.87% |
| Wellington Management Group Llp | 171,315 | 2.24% | $12.03M | +34,638 | 0.00% |
| Goldman Sachs Group Inc | 133,689 | 1.75% | $9.38M | +59,320 | 0.00% |
| Eventide Asset Management, LLC | 130,013 | 1.70% | $9.13M | – | 0.12% |
| State Street Corp | 122,178 | 1.60% | $8.58M | +13,939 | 0.00% |
| Seven Grand Managers, LLC | 120,000 | 1.57% | $8.42M | – | 0.34% |
| Great Point Partners LLC | 109,603 | 1.44% | $7.69M | −110,397 | 1.45% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 100 | 9M | 100.0% | 20 / 47 | 17 / 12 | 3M | 1M |
| Q1 2026 | 94 | 9M | 100.0% | 29 / 45 | 15 / 7 | 3M | 0M |
| Q4 2025 | 74 | 7M | 86.3% | 17 / 27 | 20 / 7 | 1M | 1M |
| Q3 2025 | 64 | 6M | 79.2% | 18 / 22 | 13 / 1 | 1M | 0M |
| Q2 2025 | 47 | 5M | 68.6% | 22 / 7 | 9 / 9 | 0M | 0M |
| Q1 2025 | 34 | 5M | 68.3% | 10 / 10 | 8 / 7 | 1M | 1M |
| Q4 2024 | 31 | 5M | 64.1% | 26 / 2 | 2 / 1 | 5M | 0M |
| Q3 2024 | 6 | 0M | 2.5% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q2 2024 | 6 | 0M | 2.6% | 0 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 7 | 0M | 2.8% | 3 / 1 | 1 / 4 | 0M | 0M |
| Q4 2023 | 8 | 0M | 3.0% | 2 / 3 | 1 / 0 | 0M | 0M |
| Q3 2023 | 6 | 0M | 2.5% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
87 funds held DRUG in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DRUG | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 194,417 | 2.55% | $13.65M | 0.02% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 130,013 | 1.70% | $9.13M | 0.51% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 95,655 | 1.25% | $8.42M | 0.14% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 81,231 | 1.06% | $5.95M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 69,591 | 0.91% | $4.89M | 0.03% | Jun 30, 2026 |
| Driehaus Micro Cap Growth Fund | 41,568 | 0.54% | $2.92M | 0.49% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 35,879 | 0.47% | $3.16M | 0.02% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 28,882 | 0.38% | $2.54M | 0.14% | May 31, 2026 |
| iShares Micro-Cap ETF | 24,919 | 0.33% | $1.75M | 0.12% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 24,274 | 0.32% | $1.70M | 3.84% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 22,267 | 0.29% | $1.56M | 0.04% | Jun 30, 2026 |
| Adara Smaller Companies Fund | 20,238 | 0.27% | $1.78M | 0.22% | May 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 18,815 | 0.25% | $1.38M | 0.14% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 18,032 | 0.24% | $1.32M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 13,852 | 0.18% | $972.41K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bihua Chen | – | 452,409 | 5.92% | Apr 30, 2026 |
| Cormorant Global Healthcare Master Fund, LP | – | 864,743 | 11.32% | Apr 30, 2026 |
| Cormorant Asset Management, LP | – | 950,000 | 12.44% | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP – | Apr 28, 2026 | Sale | −109,331 | $89.50 | $9.79M | 950,000 |
| Cormorant Asset Management, LP 10% owner | Nov 4, 2024 | Buy | +184,331 | $21.70 | $4.00M | 1,059,331 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +39,743 | $23.22 | $922.83K | 864,743 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +3,107 | $25.22 | $78.36K | 875,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +7,150 | $24.03 | $171.81K | 871,893 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +4,609 | $12.35 | $56.92K | 825,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +19,169 | $11.72 | $224.66K | 820,391 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +2,700 | $9.26 | $25.00K | 801,222 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +8,900 | $7.31 | $65.06K | 795,922 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +33,343 | $6.42 | $214.06K | 787,022 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +63,173 | $5.92 | $373.98K | 753,679 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +238,097 | $4.53 | $1.08M | 690,506 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +2,600 | $8.80 | $22.88K | 798,522 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bright Minds Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 93,618 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?